Factors affecting vaccine responses in patients with mature T/NK-cell neoplasms
Since the median age of the patients in our cohort was 74 years, we divided the patients by age of 75 years for clinical usefulness. The seroconversion rate at 3 months after the second vaccination in patients aged 75 years or older was lower than that in patients younger than 75 years of age, but the difference was not statistically significant (55.6% vs. 90.0%, Anti-SARS-CoV-2 S antibody titers at 3 months and 9 months after the second vaccination in patients 75 years of age or older and in patients younger than 75 years of age. Individuals who did not receive a third dose prior to the 9-month blood sampling were excluded from the analysis of 9-month blood sampling. The Mann–Whitney The vaccine response was examined in 6 patients who were receiving active treatment and 13 patients who were not receiving active treatment at the time of the second vaccination. There was no significant difference in the seroconversion rate at 3 months after the second vaccination between patients who were receiving and those who were not receiving active treatment (66.7% vs. 76.9%, 